Get alerted on the PharmaSources E-Newsletter and Pharma Sources Insight E-Compilation!
Note: You can unsubscribe from the alerts at any time.
Advertising

FDA Approves New Treatment for Paroxysmal Nocturnal Hemoglobinuria

americanpharmaceuticalreviewDecember 27, 2018

Tag: meningococcal infections , FDA , PNH , Ultomiris , ravulizumab

PharmaSources Customer Service